Try our mobile app
New analyses, including late-breaking data and presentations on CAMZYOS® (mavacamten) and Eliquis® (apixaban), reaffirm the company's steadfast dedication to tackling cardiovascular diseases
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research reinforcing the strength of its robust cardiovascular portfolio at the European Society of Cardiology(ESC) Congress, taking place in-person and virtually August 25-28, 2023. Data from clinical studies will be featured, including presentations of CAMZYOS® (mavacamten) cumulative analysis up to 120-weeks and impact to standard of care (SOC) medication from the EXPLORER cohort of the MAVA-long-term extension (LTE) study, as well as a late-breaking presentation of VALOR-HCM-LTE 56-week data, and new data from health economics outcomes research. The Bristol Myers Squibb-Pfizer Alliance will also share an observational retrospective real-world study on the clinical impact of switching or continuation of Eliquis® (apixaban) or rivaroxaban among patients with non-valvular atrial fibrillation (NVAF).
“This year’s ESC Congress provides the opportunity to present new data spanning our cardiovascular portfolio, reinforcing our ambition of bringing innovative and life-changing medicines to patients living with cardiovascular diseases,” said Roland Chen, MD, Senior Vice President and Head of Cardiovascular & Neuroscience Development, Global Drug Development. “These data demonstrate the consistency and impact of our cardiovascular medicines – ranging from treatments that have been available to patients with atrial fibrillation for over a decade to our more recent therapeutic option tackling symptomatic obstructive hypertrophic cardiomyopathy.”
Key presentations include:
Summary of Presentations Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at ESC Congress 2023 include:
Abstract Title | Primary Author | Type/# | Session Title | Time (CEST) |
Friday, August 25, 2023 | ||||
Multiplex screening for biomarkers associated with subsequent heart failure hospitalisation in patients with atrial fibrillation: insights from the ARISTOTLE trial* | Pol, T. | Moderated Poster - 3096 | Pathophysiology and Mechanisms | 8:15 AM – 9:00 AM |
Repeated measurement of the novel atrial biomarker BMP10 improves risk stratification in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial* | Gkarmiris, KI. | Moderated e-Poster - 811 | Advances in Science | 8:30 AM – 10:00 AM |
Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation: insights from the observational retrospective real-world data study* | Deitelzweig, S. | Moderated e-Poster - 3346 | Oral anticoagulation in patients with atrial fibrillation | 4:15 PM - 5:00 PM |
Sunday, August 27, 2023 | ||||
Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks | Garcia-Pavia, P. | Oral - 83538 | Contemporary management of hypertrophic cardiomyopathy | 10:15 AM – 11:15 AM |
Changes in standard of care (SOC) medication during long-term mavacamten treatment for obstructive hypertrophic cardiomyopathy (HCM): results from the EXPLORER cohort of MAVA-Long-Term Extension (LTE) | Lakdawala, N. | Moderated Poster - 83579 | Cardiomyopathies in myocardial disease | 5:15 PM – 6:00 PM |
Association between hospital volume, clinical events, resource utilization, and costs of septal myectomy and alcohol septal ablation procedures in US patients with hypertrophic cardiomyopathy | Maksabedian Hernandez, E.J. | Moderated-Poster - 86138 | Cardiomyopathies in myocardial disease | 5:15 PM – 6:00 PM |
Monday, August 28, 2023 | ||||
EXPLORER-CN – Efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy** | Tian, Z. | Oral | Late-breaking science on valve disease and hypertrophic cardiomyopathy | 5:00 PM – 5:15 PM |
VALOR-HCM 56 Week Long-term Extension Study in oHCM | Desai, M. | Oral | Late-breaking science on valve disease and hypertrophic cardiomyopathy | 5:15 PM – 5:30 PM |
*Sponsored by the Bristol Myers Squibb-Pfizer Alliance **Sponsored by LianBio
About CAMZYOS®(mavacamten) CAMZYOS® (mavacamten) is the first and only cardiac myosin inhibitor approved in the U.S., indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms, and in the European Union, indicated for the treatment of symptomatic (NYHA, class II-III) obstructive HCM in adult patients. It has also received regulatory approvals in Australia, Brazil, Canada, Great Britain, Macau, Singapore, South Korea, and Switzerland. CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin. CAMZYOS modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. CAMZYOS shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In HCM patients, myosin inhibition with CAMZYOS reduces dynamic left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF HEART FAILURE
CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.
Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF
